Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Freeline Therapeutics

    NASDAQ: FRLN · Real-Time Price · USD
    6.49
    0.01 (0.15%)
    At close: Feb 16, 2024, 9:37 PM

    Freeline Therapeutics Statistics

    Share Statistics

    Freeline Therapeutics has 4.36M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 4.36M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 26.8M

    Failed to Deliver (FTD) Shares

    n/a
    		 14

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 10.36K, so 0.24% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.36K

    Short % of Shares Out

    n/a
    		 0.24%

    Short % of Float

    n/a
    		 0.25%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.32 and the forward PE ratio is null. Freeline Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.32

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.54

    P/FCF Ratio

    n/a
    		 -0.33

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Freeline Therapeutics has an Enterprise Value (EV) of -13.18M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 0.14

    EV / EBIT

    n/a
    		 0.17

    EV / FCF

    n/a
    		 0.15

    Financial Position

    The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.11.

    Current Ratio

    n/a
    		 2.18

    Quick Ratio

    n/a
    		 1.61

    Debt / Equity

    n/a
    		 0.11

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.07

    Interest Coverage

    n/a
    		 9.55

    Financial Efficiency

    Return on Equity is -169.75% and Return on Invested Capital is -169.45%.

    Return on Equity

    n/a
    		 -169.75%

    Return on Assets

    n/a
    		 -102.69%

    Return on Invested Capital

    n/a
    		 -169.45%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-585,342.11

    Employee Count

    n/a
    		 152

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 0.1

    Taxes

    Income Tax

    n/a
    		 368K

    Effective Tax Rate

    n/a
    		 -0.42%

    Stock Price Statistics

    The stock price has increased by 0.15% in the last 52 weeks. The beta is 0.66, so Freeline Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.66

    52-Week Price Change

    n/a
    		 0.15%

    50-Day Moving Average

    n/a
    		 6.42

    200-Day Moving Average

    n/a
    		 4.69

    Relative Strength Index (RSI)

    n/a
    		 61.01

    Average Volume (20 Days)

    n/a
    		 28,144

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -1.74M

    Operating Income

    n/a
    		 -98.45M

    Net Income

    n/a
    		 -88.97M

    EBITDA

    n/a
    		 -97.17M

    EBIT

    n/a
    		 -98.92M

    Earnings Per Share (EPS)

    n/a
    		 -22.52
    Full Income Statement

    Balance Sheet

    The company has 47.28M in cash and 5.92M in debt, giving a net cash position of 41.35M.

    Cash & Cash Equivalents

    n/a
    		 47.28M

    Total Debt

    n/a
    		 5.92M

    Net Cash

    n/a
    		 41.35M

    Retained Earnings

    n/a
    		 -445.35M

    Total Assets

    n/a
    		 49.22M

    Working Capital

    n/a
    		 16.52M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -78.22M and capital expenditures -7.01M, giving a free cash flow of -85.24M.

    Operating Cash Flow

    n/a
    		 -78.22M

    Capital Expenditures

    n/a
    		 -7.01M

    Free Cash Flow

    n/a
    		 -85.24M

    FCF Per Share

    n/a
    		 -21.57
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    FRLN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -315.8%

    FCF Yield

    n/a
    		 -302.54%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for FRLN.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 12, 2023. It was a backward split with a ratio of 1:15.

    Last Split Date

    n/a
    		 May 12, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:15

    Scores

    Altman Z-Score

    n/a
    		 -16.92

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist